Treats hypertension. ANDA 213406, held by Appco. Prazosin Hydrochloride.
As of Nov 16, 2026, ANDA 213406 (Prazosin Hydrochloride), held by Appco, was first approved by FDA on Oct 21, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Prazosin hydrochloride capsules is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 21, 2022 | Original application | Approved | None posted |
| Prazosin HydrochlorideEQ 1MG BASE · capsule;oral | Prazosin Hydrochloride | Rx |
| Prazosin HydrochlorideEQ 2MG BASE · capsule;oral | Prazosin Hydrochloride | Rx |
| Prazosin HydrochlorideEQ 5MG BASE · capsule;oral | Prazosin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters